目的 伊马替尼(imatinib,IMN)包埋于托可索仑(tocofersolan,TPGS)胶束中,以提高其水溶性,并对其理化性质进行表征,及与人源耐药细胞株MCF-7/ADR的作用效果。通过TPGS胶束运输IMN进入细胞,可克服肿瘤细胞的多药耐药性,提高抗肿瘤效果,为进一步体内药效研究提供基础。方法 采用薄膜分散法制备IMN-TPGS胶束,对其粒径、电位、形态、载药量和包封率及体外释放行为进行表征,考察该胶束对MCF-7/ADR细胞的抗肿瘤效果。结果 IMN-TPGS胶束平均粒径为(22.69±2.39)nm,表面呈电中性,外观圆整,载药量为(1.55±0.06)%,包封率为(63.49±2.42)%;具有较高的耐稀释性,血清稳定性和冻干-复溶稳定性;在体外释放72 h后,累积释放度近100%,释放速率缓慢;IMN-TPGS胶束对MCF-7/ADR的IC50为12.27 μmol·L-1,细胞毒性大,细胞内药物含量高,可诱导近半数细胞凋亡。结论 IMN-TPGS胶束粒径均一,分散性良好,稳定性高,具有较强抗稀释性,有利于体液长循环,对耐药细胞株有明显的抗肿瘤效果,在一定程度上可以克服其多药耐药性。
Abstract
OBJECTIVE To embed imatinib(IMN) into micelles based on tocofersolan(TPGS) matrix , charecterize the physical and chemical properties of IMN-TPGS micelles and improve the anti-tumor effect. METHODS The thin film dispersion method was used to prepare IMN-TPGS micelles, and their particle size distribution, surface potential, morphology, drug loading, encapsulation efficiency and in vitro release behavior were characterized. The in vitro anti-tumor effect of IMN-TPGS micelles was investigated on MCF-7/ADR cells. RESULTS The average particle size of IMN-TPGS micelles was (22.69±2.39) nm, the drug loading was (1.55±0.06)%, and the encapsulation efficiency was (63.49±2.42)%. IMN-TPGS micelles with neutral surface showed a nearly sphere appearance. There was no significant change in diameter and drug loading after dilution times. IMN-TPGS micelles could be stable in the serum solution for 24 h. There was no significant difference in its particle size and encapsulation efficiency before and after freeze-drying. The in vitro cumulative release of IMN from TPGS micelles was close to 100% after 72 hours with a slow rate. The IC50 of the IMN-loaded TPGS micelles was 12.27μmol·L-1 consistent with its significant cellular uptake in MCF-7/ADR cells. CONCLUSION IMN-TPGS micelles with uniform particle size, good dispersibility and high stability, showed strong anti-dilution properties, which were conducive to the long circulation in body fluids. IMN-TPGS micelles exhibit obvious anti-tumor effects on drug-resistant cell lines, which could overcome multidrug resistance to a certain extent.
关键词
伊马替尼 /
胶束 /
托可索仑 /
多药耐药性
{{custom_keyword}} /
Key words
imatinib /
micelle /
tocofersolan /
multidrug resistance
{{custom_keyword}} /
中图分类号：
R965
R944
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SAW P E, PARK J, JON S, et al. A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin [J]. Nanomed Nanotechnol Biol Med, 2017, 13(2):713-722.
[2] KUMAR Y V, AKINCHAN K, ANITA M, et al. Engineered reversal of drug resistance in cancer cells-metastases suppressor factors as change agents [J]. Nucleic Acids Res, 2014, 42(2):764-773.
[3] BANI M R, DECIO A, GIAVAZZI R, et al. Contribution of tumor endothelial cells to drug resistance:anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists [J]. Angiogenesis, 2017, 20(2):233-241.
[4] WOJTKOWIAK J W, VERDUZCO D, SCHRAMM K J, et al. Drug resistance and cellular adaptation to tumor acidic pH microenvironment [J]. Mol Pharm, 2011, 8(6):2032-2038.
[5] MINKO T, RODRIGUEZ-RODRIGUEZ L, POZHAROV V. Nanotechnology approaches for personalized treatment of multidrug resistant cancers [J]. Adv Drug Deliv Rev, 2013,65(13-14):1880-1895.
[6] MAYER L D, SHABBITS J A. The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance [J]. Cancer Metastasis Rev, 2001, 20(1-2):87-93.
[7] BIZ W J, VIANNA D, ALINE B, et al. Imatinib mesylate affects extracellular ATP catabolism and expression of NTPDases in a chronic myeloid leukemia cell line [J]. Purinergic Signall, 2020, 16(1):29-40.
[8] SILVER T R. Imatinib mesylate (GleevecTM) reduces phlebotomy requirements in polycythemia vera [J]. Leukemia, 2003, 17(6):1186-1187.
[9] RAMAZANI F, CHEN W, NOSTRUM C V, et al. Formulation and characterization of microspheres loaded with imatinib for sustained delivery [J]. Int J Pharm, 2015, 482(1-2):123-130.
[10] CI L Q, HUANG Z G, LV F M, et al. Enhanced delivery of imatinib into vaginal mucosa via a new positively charged nanocrystal-loaded in situ hydrogel formulation for treatment of cervical cancer [J]. Pharmaceutics, 2019, 11(1):15-30. Doi:10.3390/pharmaceutics.11010015.
[11] WANG G, CHEN T E, ZHANG W, et al. Pharmaceutical prospect of D-a-tocopherol polyethyleneglycol 1000 succinate [J]. Cent South Pharm(中南药学), 2017, 15(11):1563-1567.
[12] WESTERGREN T, KALIKSTAD B. Dosage and formulation issues:oral vitamin E therapy in children [J]. Eur J Clin Pharmacol, 2010, 66(2):109-118.
[13] YANG F, HEN B, GONG L Y, et al. Progress of the vitamin E polyethylene glycol succinate in anti-tumor research [J]. J Chin Oncol (肿瘤学杂志), 2019, 25(12):1085-1089.
[14] TUGUNTAEV R G, CHEN S, ELTAHAN A S, et al. P-gp inhibition and mitochondrial impairment by dual-functional nanostructure based on vitamin E derivatives to overcome multidrug resistance [J]. ACS Appl Mater Interfaces, 2017, 9(20):16900-16912.
[15] YU L B. Preparation and evaluation of D-α-tocophrol polythylene glycol succinate-based prodrugs for overcoming multidrug resistance of cancer [D]. Wuhan:Huazhong University of Science and Technology, 2016.
[16] LIU Y, HUANG L, LIU F. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer [J]. Mol Pharm, 2010, 7(3):863-869.
[17] FAN Z, JIANG B, SHI D, et al. Selective antitumor activity of drug-free TPGS nanomicelles with ROS-induced mitochondrial cell death [J]. Int J Pharm, 2021, 594:120184. doi:10.1016/j.ijpharm.2020.120184-120199.
[18] BAO Y, YIN M, HU X, et al. A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery [J]. J Controlled Release, 2016, 235:182-194.
[19] LIGGINS R T, BURT H M. Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations [J]. Adv Drug Deliv Rev, 2002, 54(2):191-202.
[20] LO C L, HUANG C K, LIN K M, et al. Mixed micelles formed from graft and diblock copolymers for application in intracellular drug delivery [J]. Biomaterials, 2007, 28(6):1225-1235.
[21] TAN C, WANG Y, FAN W. Exploring polymeric micelles for improved delivery of anticancer agents: recent developments in preclinical studies [J]. Pharmaceutics, 2013, 5(1):201-219.
[22] ATTIA A B, ONG Z Y, HEDRICK J L, et al. Mixed micelles self-assembled from block copolymers for drug delivery [J]. Curr Opin Colloid Interface Sci, 2011, 16 (3):182-194.
[23] GHEZZI M, PESCINA S, PADULA C, et al. Polymeric micelles in drug delivery:An insight of the techniques for their characterization and assessment in biorelevant conditions [J]. J Controlled Release, 2021, 332:312-336.
[24] ZHANG Z, TAN S, FENG S S. Vitamin E TPGS as a molecular biomaterial for drug delivery [J]. Biomaterials, 2012, 33(19):4889-4906.
[25] BAGHERI M, FENS M H, KLEIJN T G, et al. In vitro and in vivo studies on HPMA-based polymeric micelles loaded with curcumin [J]. Mol Pharm, 2021, 18(3):1247-1263.
[26] KWON G S, KATAOKA K. Block copolymer micelles as long-circulating drug vehicles [J]. Adv Drug Deliv Rev, 2012, 64(2-3):295-309.
[27] WEIGEL M T, DAHMKE L, SCHEM C, et al. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells [J]. BMC Cancer, 2010, 10:412-425. Doi:10.1186/1471-2407-10-412.
[28] SHANDIZ S, KHOSRAVANI M, MOHAMMADI S, et al. Evaluation of imatinib mesylate (Gleevec) on KAI1/CD82 gene expression in breast cancer MCF-7 cells using quantitative real-time PCR [J]. Asian Pac J Trop Biomed, 2016, 6(2):159-163.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(2254 KB)
